Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection

    loading  Checking for direct PDF access through Ovid

Abstract

Background:

Metabolic syndrome (MS) identifies individuals at risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Little is known about MS and its consequences following initiation of antiretroviral therapy (ART).

Methods:

HIV-infected adults (881) initiating ART were evaluated for prevalence and incidence of MS and subsequent diagnosis of CVD and T2DM over a 3-year period. MS was defined by criteria of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Third Report; ATP-III) or of the International Diabetes Federation (IDF).

Results:

The prevalence of baseline MS was 8.5% and 7.8% (ATP-III and IDF, respectively). During follow-up, 234 (12/100 patient-years) (ATP-III) and 178 (8/100 patient-years) (IDF) progressed to MS. MS at baseline had a borderline association with increased risk of CVD [ATP-III: hazard ratio (HR), 2.56; 95% confidence interval (CI), 0.86–7.60; P = 0.095; IDF: HR, 2.89; 95% CI, 0.98–8.63; P = 0.058] and was significantly associated with an increased risk of T2DM (ATP-III: HR, 4.34; 95% CI, 1.83–10.25; P = 0.001; IDF: HR, 3.33; 95% CI, 1.35–8.17; P = 0.009). Incident MS was significantly associated with an increased risk of both CVD (ATP-III: HR, 2.73; 95% CI, 1.07–6.96; P = 0.036; IDF: HR, 3.05; 95% CI, 1.20–7.75; P = 0.019) and T2DM (ATP-III: HR, 4.89; 95% CI, 2.22–10.78; P < 0.0001; IDF: HR, 4.84; 95% CI, 2.20–10.64; P < 0.0001).

Conclusions:

Substantial progression to MS occurs within 3 years following initiation of ART. Since baseline and incident MS identifies individuals at risk for subsequent CVD and T2DM, it warrants evaluation in patients commencing ART.

Related Topics

    loading  Loading Related Articles